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STW 5 (Iberogast®) – Ein wirksamer und 
verträglicher Standard in der Therapie 
funktioneller Magen-Darm-Erkrankungen 
Zusammenfassung Funktionelle Dyspepsie (FD) und 
Reizdarmsyndrom (RDS) sind häufige Erkrankungen 
mit Einfluss auf die Lebensqualität, die evtl. eine Lang-
zeitbehandlung erfordern. Ober- und Unterbauchsym-
ptome können gemeinsam auftreten, was die Differen-
zialdiagnose und Therapie erschwert. Die Frischpflan-
zen- und Drogenauszüge im Kombinationspräparat 
STW 5 (Iberogast®) wirken auf verschiedene gastroin-
testinale Regionen und adressieren sowohl FD als auch 
RDS. Dieser Review beschreibt das Sicherheitsprofil von 
STW 5 und bezieht sich auf zwölf seit 1990 durchgeführ-
te Studien bei diesen Indikationen. Doppelblinde und 
randomisierte Studien gegen Plazebo und/oder aktive 
Kontrolle fanden statistisch signifikante und klinisch re-
levante Effekte gegenüber Plazebo bzw. eine zu einem 
Standardprokinetikum vergleichbare Wirkung. Diese Ef-
fekte wurden in nicht-interventionellen bzw. retrospek-
tiven Studien bestätigt. Klinische Studien unterschied-
lichen Designs untersuchten das Verträglichkeitsprofil 
von STW 5. Die Inzidenz unerwünschter Arzneimittel-
wirkungen in diesen Studien betrug 0,04  %. Das welt-
weite Spontanmeldesystem bestätigte dieses Profil. STW 
5 weist eine vorteilhafte Verträglichkeit auf, die für eine 
Langzeittherapie zu fordern ist.
Schlüsselwörter: Funktionelle Dyspepsie/Reizmagen, 
Reizdarm, Iberogast/STW 5, Iberis amara, Review
Summary Functional dyspepsia (FD) and irritable 
bowel syndrome (IBS) are frequent disorders affecting 
quality of life. They often require long-term treatment. 
Abdominal symptoms of both disorders can overlap, 
making differential diagnosis and treatment challeng-
ing. The extracts of the herbal combination preparation 
STW 5 (Iberogast®) exert pharmacological effects in dif-
ferent gastrointestinal regions and can address symp-
toms of both FD and IBS. This review summarizes safety 
and efficacy data of 12 clinical trials using STW 5 in FD 
and IBS since 1990. Double-blind and randomized stud-
ies versus placebo or active control found statistically 
significant effects of STW 5 on patients’ symptoms with 
a comparable efficacy to a standard prokinetic. Non-in-
terventional and retrospective studies confirmed these 
effects. Various studies evaluated the tolerability profile 
of STW 5: the incidence of adverse drug reactions was 
0.04  %. The worldwide spontaneous reporting system 
confirmed this profile. STW 5 has a favorable tolerability 
which is relevant for long-term treatment.
Keywords: Functional dyspepsia, Irritable bowel syn-
drome, Iberogast/STW 5, Iberis amara, Review
Introduction
Functional dyspepsia and irritable bowel syndrome 
(IBS) are the most frequent functional gastrointestinal 
disorders. In a Western population, their prevalence is 
estimated at approximately 10–20 % each [1]. Symptoms 
of both disorders may overlap, showing components of 
functional dyspepsia and of IBS at one time [2]. Func-
tional gastrointestinal disorders are frequently perceived 
as psychological or psychosomatic disorders. They are 
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the box to which patients are allocated, if organic disease 
is absent. In an attempt to find something “real”, patients 
may undergo unneeded diagnostic approaches [3].
Since 1987, scientists and clinicians have worked on 
the understanding and classification of functional gas-
trointestinal disorders and have developed the Rome cri-
teria, which are now applied for diagnosis [4]. The current 
Rome III diagnostic criteria classify functional gastroin-
testinal disorders into several categories according to the 
regional location of symptoms, the predominant symp-
toms, and the age. Functional gastrointestinal disorders 
are currently explained by a biopsychological model, 
which “allows for symptoms to be both physiologically 
multi-determined and modifiable by sociocultural and 
psychosocial influences”. In this model, psychosocial fac-
tors and physiology are interlinked through the “brain-
gut axis”, with the elements influenced by genetic and 
environmental factors (Fig. 1) [3]. The Rome III diagnos-
tic criteria for functional dyspepsia and IBS are shown in 
Tables 1 and 2 [5, 6].
The therapy for functional dyspepsia and IBS is multi-
faceted and includes patient education, dietary recom-
mendations, physical exercise, relaxation, and stress 
management. If such non-pharmacological measures 
are not successful, pharmacologic interventions like 
proton pump inhibitors, prokinetic drugs, antibiotics 
for the eradication of Helicobacter pylori, if positive, 
antidiarrhoics, dietary fibers, bulking agents, anticholin-
ergic spasmolytics, tricyclic antidepressants, and herbal 
drugs are recommended [1, 2, 7, 8]. With the exception 
of herbal combination medicines, pharmacological 
drugs mostly treat only one symptom at a time and thus 
cannot address overlapping and variable complaints. 
In addition, side-effects with chronic treatment can be 
observed.
Functional gastrointestinal disorders are not life-
threatening and in the strict sense of the word also not 
debilitating diseases. Accordingly, they are not desperate 
illnesses, which require desperate remedies. However, 
functional gastrointestinal disorders relevantly reduce 
the quality of life and often require chronic therapy [9]. 
Thus it is important not only to supply effective therapy to 
patients, but also to focus on the long-term tolerability.
The herbal combination preparation STW 5 
(Iberogast®, Steigerwald Arzneimittelwerk GmbH, Darm-
stadt, Germany) has been comprehensively studied for 
the treatment of functional gastrointestinal disorders of 
the upper and lower abdomen. STW 5 contains alcoholic 
extracts of Iberis amara totalis recens, Angelicae radix, 
Cardui mariae fructus, Chelidonii herba, Liquiritiae radix, 
Matricariae flos, Melissae folium, Carvi fructus and Men-
thae piperitae folium and has been used for the therapy of 
functional gastrointestinal disorders for five decades. The 
extracts exert different proven pharmacological effects 
on different regions of the gastrointestinal tract and thus 
address the whole symptom complex of functional dys-
pepsia syndrome and IBS [10]. The tolerability of STW 5 
was favorable both in clinical studies and in post-mar-
keting use.
This review was performed to evaluate the available 
clinical data on STW 5 with a focus also on its tolerability 
profile.
Material and methods
We reviewed the following clinical studies and report 
information on study design, patient characteristics and 
efficacy and safety outcomes:
•	 	Six	 controlled	 and	 randomized	 studies	 with	 STW	 5,	
five in functional dyspepsia and one in IBS [11–16]. 
The studies in functional dyspepsia have also been in-
cluded in several meta-analyses [17–19].
•	 	Two	 post-marketing	 surveillance	 studies	 in	 various	
gastrointestinal diseases, including functional dys-
pepsia and IBS, and one retrospective cohort study in 
functional dyspepsia [20–22].
•	 	Two	retrospective	surveillance	studies	and	one	non-
interventional study in children with gastrointestinal 
complaints, including functional dyspepsia and IBS 
[23–25].
Fig. 1 Biopsychosocial conceptualization of functional gas-
trointestinal disorders [3]
CNS: Central nervous system
ENS: Enteric nervous system
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Table 1. Diagnostic criteria of functional dyspepsia [5]
Diagnostic criteria of functional dyspepsia
1. One or more of the following:




2.  No evidence of structural disease (including at upper endoscopy) that is 
likely to explain the symptoms
The criteria have to be fulfilled for the last 3 months with symptom onset at 
least 6 months before diagnosis
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Interventional studies had been reviewed by the appro-
priate ethics committee and were performed in accor-
dance with the ethical standards laid down in the 
Declaration of Helsinki. All patients gave their informed 
consent prior to their inclusion in the studies. Eleven 
older studies with STW 5 performed before 1990, when 
the first European GCP guideline was adopted, were not 
taken into account.
Results
The characteristics of the studies are tabulated in Table 3. 
Overall, 413 patients were treated with STW 5 in random-
ized controlled studies, about 5,795 patients in prospec-
tive non-interventional studies, and more than 40,000 
children in retrospective database surveillances.
Comparative clinical studies
Functional dyspepsia
Four clinical studies evaluated STW 5 versus placebo 
and one study tested the non-inferiority of STW 5 to the 
prokinetic drug cisapride. A panel of gastroenterological 
experts participated in planning the studies and devel-
oped the primary efficacy criterion, the gastrointestinal 
symptom score (GIS). This score is a summary score con-
sisting of ten gastrointestinal symptoms, which are eval-
uated on five-point Likert scales. The GIS was validated 
and is sensitive, responsive, and specific for functional 
dyspepsia [26]. All studies had a similar design.
Von Arnim et al. [11, 27] performed a randomized, 
double-blind, placebo-controlled study, which included 
315 patients with functional dyspepsia diagnosed accord-
ing to the Rome II criteria. After a washout of 7 days, the 
patients were randomized to an 8 weeks treatment period 
with either STW 5 3 × 20  drops/day or placebo. Patients 
were followed up for 6 months. The primary endpoint was 
the change of the GIS over the treatment period. The GIS 
improved in both groups (see Fig. 2). After 4 and 8 weeks 
of treatment, the improvement was significantly higher in 
the STW 5 group compared to placebo and the difference 
between the two groups was clinically relevant. Investi-
gators’ and patients’ global assessments confirmed the 
significant superiority of STW 5. On average, patients 
treated with STW 5 remained recurrence-free longer 
than patients who had received placebo. Though in the 
very good and good categories of tolerability assessments 
by patients, there was a slight imbalance in favor of pla-
cebo, the overall tolerability of STW 5 and placebo were 
comparable (see Fig.  3). No clinically relevant changes 
of laboratory or vital parameters and no serious adverse 
events occurred. The proportion of patients with docu-
mented adverse events was practically identical in both 
treatment groups. Five patients reported seven adverse 
events, in which a causal relationship to STW 5 could 
not be excluded (abdominal pain, pruritus, sore throat, 
alopecia, hypersensitivity, hypertension, gastrointestinal 
pain).
The other three studies in patients with functional 
dyspepsia comparing STW 5 to placebo showed basically 
similar results, i.e. a statistically significant and clinically 
relevant superiority of STW 5 versus placebo as deter-
mined by the GIS and an almost identical proportion of 
patients with adverse events in both treatment groups. 
Adverse events at least possibly related to STW 5 reported 
in these studies were esophagitis, bronchitis, diarrhea, 
nausea, stomatitis, and abdominal pain [12–14].
One of the studies examined gastric emptying as sec-
ondary parameter with the help of the 13C octanoic acid 
breath test for the assessment of the gastric half-empty-
ing time [14]. The findings from this study suggested that 
the clinical effects of STW 5 were not simply mediated 
by accelerating gastric emptying, but by more complex 
processes, reflecting the multi-faceted pharmacological 
profile of the drug.
The studies of STW 5 versus placebo with patients 
suffering from functional dyspepsia were sufficiently 
comparable in design to be submitted to several meta-
analyses [17–19]. These meta-analyses detected a signifi-
cant efficacy of STW 5. The latest and largest included 
637 patients and found a standardized mean difference 
of − 1.1, indicating a large and clinically relevant effect 
(p = 0.0005), although there was statistically significant 
heterogeneity between studies [19].
One clinical trial compared STW 5 to the prokinetic 
drug cisapride 3 × 20  mg/day [15]. To ensure double-
blind conditions, this study used a double dummy 
design. One-hundred eighty-six patients with functional 
dyspepsia of the dysmotility type were enrolled and 
received STW 5, cisapride, or a research compound for 
4 weeks after a 1-week washout phase. Patients were fol-
lowed up for 6 months. Like in the placebo-controlled 
studies, the primary endpoint was the change of the GIS 
during the treatment period. During treatment, the GIS 
Table 2. Diagnostic criteria of irritable bowel syndrome [6]
Diagnostic criteria of irritable bowel syndrome
Recurrent abdominal pain or discomforta at least 3 days per month in the 
last 3 months associated with two or more of the following:
1. Improvement with defecation
2. Onset associated with a change in frequency of stool
3. Onset associated with a change in form (appearance) of stool
Supportive symptoms that are not part of the diagnostic criteria include
1.  Abnormal stool frequency (≤ 3 bowel movements per week or > 3 bowel 
movements per day)
2. Abnormal stool form (lumpy/hard stool or loose/watery stool)
3. Defecation straining
4. Urgency
5. Feeling of incomplete bowel movement, passing mucus, bloating
aDiscomfort means an uncomfortable sensation not described as pain. The 
criteria have to be fulfilled for the last 3 months with symptom onset at 
least 6 months prior to diagnosis
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decreased significantly in both groups: from comparable 
baseline scores of 14.3–14.5 points, the GIS decreased to 
2.3 points in the STW 5 group and to 3.5 in the cisapride 
group, showing a numerical superiority of STW 5 and a 
statistically confirmed non-inferiority to cisapride (see 
Fig.  4). Patients, who were symptom-free after treat-
ment, were evaluated for recurrence during the 6-month 
follow-up period. There were no significant differences 
between the groups in this parameter. A further second-
ary endpoint, the efficacy assessments by investigators 
and patients, again showed comparable results for STW 
5 and cisapride. The tolerability of STW 5 was assessed 
as being very good or good by more than 93 % of investi-
gators and patients; in the cisapride group, this propor-
tion was between 81 and 91  %. More patients reported 
adverse events in the cisapride group (33 %) compared to 
the STW 5 group (21 %). Two adverse events in the STW 
5 group were classified as having a probable causal rela-
tion relationship to the study medication (abdominal 
cramps; dizziness and nausea), whereas in the cisapride 
group one such adverse event was reported (diarrhea).
IBS
One randomized, double-blind, and placebo-controlled 
clinical study analyzed the efficacy and safety of STW 5 
in IBS [16]. As one primary efficacy endpoint, the study 
used an abdominal symptom score developed by a gas-
troenterological expert panel, which included eight IBS-
specific symptoms evaluated on four-point Likert scale. 
Two-hundred and eight patients underwent a 1-week 
Table 3. Characteristics of studies with STW 5, which were performed since 1990, when the first European GCP guideline 
was adopted
First author/year/ref. Reference drug/s Study design Therapy phase/follow-up Patients total/indication (Co-)Primary efficacy 
endpoint/s




2 weeks washout 243 Change of GIS, change of 
pain profile4 weeks treatment Functional dyspepsia




1-week washout 60 Change of GIS
4 weeks treatment Functional dyspepsia





1-week washout 183 Change of GIS
4 weeks treatment Functional dyspepsia 
(dysmotility type)6 months follow-up
von Arnim [11] Placebo Multi-centre, double-
blind, randomized
1-week washout 308 Change of GIS
8 weeks treatment Functional dyspepsia
6 months follow-up
Braden [14] Placebo Multi-centre, double-
blind, randomized
1-week washout 103 Change of GIS, second-
ary: gastric half-emptying 
time via 13C-octanoic acid 
breath test
4 weeks treatment Functional dyspepsia




1-week washout 208 Change of abdominal 
symptom profile, change of 
abdominal pain profile
4 weeks treatment Irritable bowel syndrome








Raedsch [22] Metoclopramide Retrospective cohort 
study
Not applicable 961 Change of GIS
Functional dyspepsia
Leichtle [24] – Retrospective database 
surveillance
Not applicable 40,961 children 
≤ 12 year




Gundermann [23] – Retrospective database 
surveillance
Not applicable 2,350 children ≤ 12 year Global effectiveness and 
tolerability (physicians)Gastrointestinal com-
plaints
Vinson [25] – Non-interventional study Approx. 1-week 
treatment
980 children 3–14 year Change of GIS
Functional gastrointesti-
nal disorders
GIS gastrointestinal symptom profile
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washout phase and were then randomized to STW 5, 
two research compounds, or placebo for 4 weeks. STW 
5 reduced the IBS symptom score by 1.5 points more 
than placebo, a clinically relevant superiority that was 
also statistically significant (p < 0.0004). The co-primary 
endpoint abdominal pain, evaluated on four-point Lik-
ert scales for the four abdominal quadrants, showed 
comparable results and again a statistically significant 
superiority of STW 5 versus placebo. The tolerability as 
assessed by investigators was generally ‘very good’ or 
‘good’ (STW 5: 98 %; placebo: 89 %), with no essential dif-
ferences to patients’ assessments. There was one adverse 
drug reaction in the STW 5 group (constipation). No seri-
ous adverse events were reported and blood chemistry 
before and after treatment showed no clinically relevant 
variations.
Observational studies
Two non-interventional studies with a comparable design 
enrolled patients with functional dyspepsia (n = 2267) or 
IBS (n = 2548) [20, 21]. In both studies, patients received 
STW 5 for up to 4 weeks. In functional dyspepsia, 27 % of 
patients discontinued therapy after 1 week for freedom of 
symptoms. The GIS sum score decreased on average by 
78 %. In IBS, the single symptoms of the abdominal sum 
score decreased by 65–80  % each. Approximately 80  % 
of physicians and patients assessed the effectiveness of 
STW 5 as very good or good. There were no adverse drug 
reactions to or interactions with STW 5 documented in 
these studies.
A retrospective cohort study analyzed 961 patients, 
who had received STW 5 or metoclopramide in the rec-
ommended dose for functional dyspepsia [22]. The pri-
mary endpoint of this analysis was the improvement 
of GIS, outcome parameters included the number of 
symptom-reef patients after therapy and the duration of 
inability to work. There were significantly more symp-
tom-free patients after therapy with STW 5 compared to 
metoclopramide (72 versus 63 %; p < 0.05). Furthermore, 
the duration of inability to work was significantly shorter 
under STW 5 than under metoclopramide (median 1 
day versus 3 days; p < 0.001). There were no adverse drug 
reactions to STW 5, but five patients receiving metoclo-
pramide reported vertigo and dizziness. In line with these 
results, 90 % of physicians rated the tolerability of STW 5 
as very good, compared to 71 % for metoclopramide.
Studies in children
Two retrospective database surveillance studies col-
lected data on the use of STW 5 in children up to 12 years 
of age with gastrointestinal complaints including func-
tional dyspepsia and irritable bowel disease. The studies 
documented 40,961 and 2,350 patients, respectively, and 
both studies used a four-point Likert scale for an assess-
Fig. 3 Patients’ tolerability assessment of STW 5 (Iberogast®) 



























Fig. 4 Gastrointestinal Symptom Profile of STW 5 (Iberogast®) 






















            
Fig. 2 Gastrointestinal Symptom Profile of STW 5 (Iberogast®) 
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ment of efficacy [23, 24]. The physicians judged effective-
ness to be very good or good in 88 and 96 % of patients, 
respectively. Both studies did not detect adverse drug 
reactions to or interactions with STW 5.
A more recent non-interventional study included 980 
children (age 3–14 years) with functional gastrointestinal 
disorders preferably diagnosed by the Rome III criteria 
and eligible to treatment with STW 5 [25]. Patients were 
followed for approximately 1 week. The GIS, extended 
by four lower abdominal symptoms, served as primary 
endpoint for clinical effectiveness. Most patients were 
treated for IBS (43 %) or functional dyspepsia syndrome 
(26  %). The symptom score decreased by 76  % during 
the treatment period. The decrease in symptoms was 
similar for the different age groups, genders, and indica-
tions. Patients with a shorter duration of complaints had 
a lower score at study end (p < 0.0001). The global treat-
ment effect was assessed as good or very good by 87–89 % 
of patients/parents and physicians. Physicians rated the 
global tolerability as very good or good for 95  % of the 
patients. Adverse events assessed as probably or possibly 
related to STW 5 were nausea, abdominal pain, increased 
gastrointestinal complaints, and vomiting. One patient 
experienced skin rash following the concomitant appli-
cation of penicillin. These events were non-serious.
Safety overview
The safety profile of STW 5 was extensively evaluated in 
pre-clinical and in controlled and non-interventional 
or retrospective clinical studies. Pre-clinical evaluations 
included acute, subchronic, and chronic toxicity, with 
a specific focus on hepatotoxicity, reproductive toxic-
ity, fertility, embryo- and fetotoxicity, mutagenicity, and 
cytotoxicity and showed no indications of safety signals 
relevant for human use [10, 28].
Table 4 shows the number of adverse events observed 
in the controlled and non-interventional or retrospective 
clinical studies reviewed above, in which the investiga-
tors considered a causal relationship to STW 5 as at least 
possible (i.e. the adverse events classified as adverse drug 
reactions). The incidence was 0.04  % and the adverse 
drug reactions documented were (in alphabetical order) 
abdominal cramps, abdominal pain, alopecia, bronchi-
tis, constipation, diarrhea, dizziness, gastrointestinal 
complaints increased, gastrointestinal pain, hypersen-
sitivity, hypertension, nausea, esophagitis, pruritus, skin 
rash, sore throat, stomatitis, and vomiting. No serious 
adverse drug reactions occurred and the studies also 
found no clinically relevant deviations of laboratory val-
ues. STW 5 was well tolerated in the populations exam-
ined, independent of concomitant diseases and without 
drug interactions.
In addition to the clinical or observational studies 
included in Table  4, the spontaneous reporting system 
in Germany and worldwide elicited a comparatively very 
small number of adverse events assessed as possess-
ing a possible or probable causal relationship to STW 5 
(n = 111), given that the exposed cohort is estimated at 
more than 25 million patients since the market launch of 
STW 5 over 50 years ago. The summary of product char-
acteristics of STW 5 complements this information by 
specifying that hypersensitivity reactions may occur very 
rarely and may take the form of pruritus, dyspnea, or skin 
reactions in pre-disposed patients [28].
Discussion
On one hand, there is a widespread perception of herbal 
remedies as being only mild and moderately effective or 
not evidence based at all. On the other hand, some of the 
pharmacologically most active—and toxic—drugs are 
or have been derived from plants, among them aspirin, 
digitalis, colchicine, and the taxanes. Accordingly, in 
Europe herbal drugs have to meet regulatory require-
ments comparable to chemical or biopharmaceutical 
drugs. This means that they are required to undergo pre-
clinical and clinical studies showing their safety and effi-
cacy, before they are allowed to be sold or to remain on 
the markets. Under certain conditions, herbal medicines 
lacking a sufficiently scientific basis and evidence of effi-
cacy may be marketed as traditionally used medicines 
[29]. It should furthermore be considered that efficacy 
is not identical to effectiveness. Roughly speaking, effec-
tiveness describes an improvement of symptoms over 
time, whereas efficacy describes the course of symptoms 
in comparison to an active control or to a placebo group. 
Efficacy is thus effectiveness ‘cleaned’ of confounding 
Table 4. Adverse drug reactions to STW 5 in clinical and observational studies
Study type and no. of studies No. of patients treated with STW 5 No. of adverse drug reactions to STW 5
Randomized controlled studies in FD (n = 5) or IBS (n = 1)  413 15
Non-interventional studies in FD or IBS (n = 2) 4,815 0
Retrospective cohort study in FD (n = 1)  490 0
Retrospective database surveillances in children with gastrointestinal complaints 
including FD and IBS (n = 2)
43,311 0




FD Functional dyspepsia, IBS Irritable bowel syndrome
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effects like the natural course of the disease or placebo 
effects.
Treatment of functional gastrointestinal disorders 
remains a major challenge as pathomechanisms are 
complex. Thus, a multi-target approach is likely to be 
more successful than a drug directed to an individual 
target [30]. STW 5 as an herbal combination preparation 
with individually active components [31] has not only 
shown its effectiveness in improving symptoms over time 
in non-interventional studies as well as in retrospective 
database surveillances. It also passed the higher hurdle 
of proving its efficacy in studies versus placebo and cis-
apride as an active control. The efficacy observed was 
clinically relevant, as indicated by the effect size versus 
placebo as well as by an overall similar and even numeri-
cally superior effect when compared to cisapride.
The prokinetic cisapride was a standard for the treat-
ment of functional (upper) gastrointestinal disorders 
before its withdrawal from most markets for safety rea-
sons, namely, a prolongation of the QT time and result-
ing cardiac arrhythmia. Two other drugs of this class, 
domperidone and metoclopramide, have recently 
undergone labeling changes or are currently under 
review by the European Medicines Agency due to neu-
rological and/or cardiovascular events [32, 33]. Other 
drugs for treating functional gastrointestinal disorders 
currently recommended in guidelines are proton pump 
inhibitors, antidiarrhoics, anticholinergic spasmolytics, 
tricyclic antidepressants, and herbal drugs [1, 2, 7, 8]. 
All possess specific tolerability issues which have to be 
evaluated and considered when selecting a suitable ther-
apy for patients. Proton pump inhibitors tend to be over 
utilized. They have been associated with rebound acid 
hypersecretion, which may aggravate the symptoms of 
functional dyspepsia [34], whereas the compliance with 
spasmolytics like mebeverine, and also with tricyclic 
antidepressants as drugs of the last resort for functional 
gastrointestinal disorders, may be limited by their char-
acteristic therapeutic profile [1, 2, 7, 8]. In addition to 
these safety issues, the drugs enumerated are rarely ade-
quate for patients suffering from mixed complaints of the 
upper and lower gastrointestinal tract, as they address 
only one symptom at a time. The combination of drugs 
helpful for symptoms both of the upper and lower abdo-
men will generally further increase the side-effects the 
patient has to tolerate.
In several countries, STW 5 is approved as the only 
product both covering functional dyspepsia as well as 
IBS. It is furthermore included in the therapy guidelines 
for both upper and lower functional gastrointestinal dis-
orders [7, 35]. STW 5 has been thoroughly evaluated for 
tolerability over approximately five decades. Pre-clinical 
and clinical studies have especially searched for signals 
of hepatotoxicity and abnormal liver function tests, as 
herbal drugs may possess hepatotoxic effects. They have 
shown that STW 5 has no such effects. For celandine 
herbs, very rare and reversible dose-dependent cases 
of hepatic side effects had been reported. However, the 
daily doses for which these hepatic side effects of cel-
andine herbs have been described are approximately 
100–200 times higher than those applied with STW 5. Fur-
thermore, interventional and non-interventional clini-
cal studies with STW 5 as well as database surveillances 
specifically assessed liver function as a safety parameter. 
These studies under controlled conditions found no hep-
atotoxicity cases associated temporally or causally with 
STW 5. The only adverse reactions considered attribut-
able to STW 5 are hypersensitivity reactions as described 
in the summary of product characteristics. They have 
been observed very rarely in predisposed patients and 
may take the form of pruritus, dyspnea, or skin reac-
tions. Thus, STW 5 shows the favorable tolerability profile 
important for a preparation used for functional gastro-
intestinal disorders, because the chronic nature of these 
diseases often requires long-term therapy.
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